Secretory carcinoma of the breast

Tavassoli, F. A.; Norris, Henry J.

doi:10.1002/1097-0142(19800501)45:9<2404::aid-cncr2820450928>3.0.co;2-8

Cited by 206 publications

(171 citation statements)

References 7 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…Cytologically, the cells are bland, have vesicular nuclei and abundant pale-pink granular or vacuolated cytoplasm. 1,2 Following the initial publication describing mammary analog secretory carcinoma, other investigators began to look back at their own institutional cases in order to reanalyze some of their salivary gland tumors. Acinic cell carcinomas, adenocarcinomas, not otherwise specified (NOS), polymorphous lowgrade adenocarcinomas, mucoepidermoid carcinomas, and cystadenocarcinomas are examples of cases re-evaluated in a small number of recently published studies, describing additional cases of mammary analog secretory carcinoma.…”

mentioning

confidence: 99%

Searching for mammary analog secretory carcinoma of salivary gland among its mimics

et al. 2014

View full text Add to dashboard Cite

Mammary analog secretory carcinoma of salivary gland is a recently described entity with unique morphologic, clinical, and genetic characteristics, including the characteristic t(12;15)(p13;q25) with ETV6-NTRK3 translocation found in secretory carcinomas of the breast. Before their initial description, these salivary gland tumors were generally diagnosed as acinic cell carcinoma or adenocarcinoma. For the purpose of this study, all cases of salivary gland acinic cell carcinoma, cribriform cystadenocarcinoma, and adenocarcinoma, not otherwise specified (NOS), diagnosed over a 10-year period were retrieved from our surgical pathology files. There were a total of 11 cases diagnosed as acinic cell carcinoma, 10 cases of adenocarcinoma, NOS, and 6 cases of cribriform cystadenocarcinoma. All slides were reviewed by two pathologists (AP, CGF) and tumors that show morphologic features of mammary analog secretory carcinoma according to the recent literature were selected. This process narrowed down the initial number to six cases originally diagnosed as acinic cell carcinoma, three cases originally diagnosed as adenocarcinoma, NOS, and one case originally diagnosed as cribriform cystadenocarcinoma. The 10 cases were subjected to immunohistochemistry for S-100, mammaglobin, and ANO1, as well as fluorescence in situ hybridization analysis for t(12;15)(p13;q25) with ETV6-NTRK3 fusion rearrangement. The ETV6-NTRK3 gene rearrangement was detected in three tumors. These three tumors, initially diagnosed as acinic cell carcinomas, stained positive for S-100 and mammaglobin, and negative for ANO1 by immunohistochemistry. Two of the three patients were male (2/3). In summary, mammary analog secretory carcinoma is a newly described diagnostic entity that should be in the differential diagnosis of salivary gland tumors that morphologically mimic other neoplasms, mainly acinic cell carcinomas. They differ from conventional acinic cell tumors immunohistochemically and molecularly. Positivity for mammaglobin and S-100, and negativity for ANO1 are useful screening tools before confirmatory molecular studies.

show abstract

mentioning

confidence: 99%

Searching for mammary analog secretory carcinoma of salivary gland among its mimics

et al. 2014

View full text Add to dashboard Cite

show abstract

“…A total of 27 cases (including 2 cases from our study, see Table 3) of male patients with secretory breast carcinoma could be identified in the literature. 2,3,6,9,23,[25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] Most affected patients were children and adolescents with a median age of 27 years. The tumors are usually located subareolarly.…”

Section: Discussionmentioning

confidence: 99%

“…For patients over 20 years old, an initial simple mastectomy with axillary node dissection might be adequate. 2 However, recently the technique of sentinel lymph node biopsy has replaced conventional axillary lymph node dissection to become the standard of care for early breast cancer. Thus, conservative surgery (adequate local excision or quadrantectomy) with sentinel lymph node biopsy has been chosen by some surgeons when neoplasms are smaller than 20 mm, and simple mastectomy with sentinel lymph node biopsy has been preferred for neoplasms larger than 20 mm.…”

Section: Discussionmentioning

confidence: 99%

Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature

Xiao

Yang

et al. 2012

Modern Pathology

View full text Add to dashboard Cite

Secretory breast carcinoma is a rare breast cancer with indolent clinical behavior. Recent research showed that secretory breast carcinoma belongs to the phenotypic spectrum of basal-like breast carcinomas. In this study, a clinicopathological and immunophenotypic analysis of secretory breast carcinomas from 15 Chinese patients was conducted. This patient group consisted of 2 males and 13 females, with ages ranging from 10 to 67 years old (median, 36 years old). All patients presented with a painless and firm mass. Tumor size ranged from 10 to 55 mm. Most tumors were located in the outer upper quadrant of the breast. Two patients (2 of 13, 15%) displayed positive axillary lymph nodes. At the microscopic level, the presence of intracellular and extracellular secretory material was the most remarkable feature. Most cases showed mild dysplasia cytologically. All cases were negative for estrogen receptor, progesterone receptor and HER2. The expression rate of the basal-like marker (CK5/6 or epidermal growth factor receptor) was 87% (13 of 15). The basal-like phenotype was identified in 13 cases (87%). Follow-up time ranged from 10 to 55 months (median, 19 months). None of the cases had evidence of recurrence and metastasis. Our study reveals that secretory breast carcinoma is a distinct subset of invasive breast carcinoma, with expression of basal-like markers. It should be noted that secretory breast carcinoma is different from conventional basal-like breast carcinomas. Future studies are required to further understand the prognostic significance of the basal-like markers expression in secretory breast carcinomas.

show abstract

“…McDivitt and Stewart [1] in 1966 recognized an uncommon variety of mammary carcinoma in children, which they designated as 'juvenile carcinomas'. Subsequently in 1980, Tavassoli and Norris [2] reported 19 cases in patients ranging in age from 9 to 69 years old. Based on this they recommended replacing the term 'juvenile carcinoma' with the descriptive term 'secretory carcinoma'.…”

Section: Discussionmentioning

confidence: 99%

Secretory Carcinoma of Breast in a Patient Treated for Differentiated Thyroid Carcinoma—A Diagnostic Dilemma

Ganesh

Muralee

Saxena

et al. 2014

Indian J Surg Oncol

View full text Add to dashboard Cite

Secretory carcinoma of the breast is a rare entity accounting for less than 1 % of all infiltrating breast carcinomas. Though initially considered as "juvenile breast carcinoma", due to its occurrence predominantly in pediatric population, it was later found to present in other age groups as well. We report a case of secretory carcinoma breast in a middle aged woman who had undergone treatment for papillary carcinoma of thyroid previously. The uniqueness of this malignancy and the diagnostic dilemma due to patient's past medical history, are discussed in detail.

show abstract

Secretory carcinoma of the breast

Cited by 206 publications

References 7 publications

Searching for mammary analog secretory carcinoma of salivary gland among its mimics

Searching for mammary analog secretory carcinoma of salivary gland among its mimics

Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature

Secretory Carcinoma of Breast in a Patient Treated for Differentiated Thyroid Carcinoma—A Diagnostic Dilemma

Contact Info

Product

Resources

About